These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 16515857)
21. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Mintzer S; Boppana P; Toguri J; DeSantis A Epilepsia; 2006 Mar; 47(3):510-5. PubMed ID: 16529614 [TBL] [Abstract][Full Text] [Related]
22. First Analysis of the Association Between CYP3A4/5, ABCB1 Genetic Polymorphisms and Oxcarbazepine Metabolism and Transport in Chinese Epileptic Patients with Oxcarbazepine Monotherapy and Bitherapy. Wang P; Yin T; Ma HY; Liu DQ; Sheng YA; Zhou BT J Pharm Pharm Sci; 2015; 18(3):256-65. PubMed ID: 26517132 [TBL] [Abstract][Full Text] [Related]
23. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632 [TBL] [Abstract][Full Text] [Related]
24. [Pharmacokinetic variability of oxcarbazepine in epileptic patients]. Viola MS; Bercellini MA; Saidón P; Rubio MC Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701 [TBL] [Abstract][Full Text] [Related]
25. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Marchi N; Guiso G; Rizzi M; Pirker S; Novak K; Czech T; Baumgartner C; Janigro D; Caccia S; Vezzani A Epilepsia; 2005 Oct; 46(10):1613-9. PubMed ID: 16190932 [TBL] [Abstract][Full Text] [Related]
26. Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients. May TW; Rambeck B; Sälke-Kellermann A Acta Neurol Scand; 1996 Jun; 93(6):393-7. PubMed ID: 8836299 [TBL] [Abstract][Full Text] [Related]
27. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739 [TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. Jang Y; Yoon S; Kim TJ; Lee S; Yu KS; Jang IJ; Chu K; Lee SK Sci Rep; 2021 Mar; 11(1):6370. PubMed ID: 33737678 [TBL] [Abstract][Full Text] [Related]
29. Plasma level monitoring of oxcarbazepine in epileptic patients. González-Esquivel DF; Ortega-Gavilán M; Alcántara-López G; Jung-Cook H Arch Med Res; 2000; 31(2):202-5. PubMed ID: 10880728 [TBL] [Abstract][Full Text] [Related]
30. Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. Maschio M; Albani F; Jandolo B; Zarabla A; Contin M; Dinapoli L; Fabi A; Pace A; Baruzzi A J Neurooncol; 2008 Nov; 90(2):217-21. PubMed ID: 18612799 [TBL] [Abstract][Full Text] [Related]
31. Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine. Cansu A; Serdaroglu A; Biberoglu G; Tumer L; Hirfanoglu TL; Ezgu FS; Hasanoglu A Epileptic Disord; 2011 Dec; 13(4):394-400. PubMed ID: 22258044 [TBL] [Abstract][Full Text] [Related]
32. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Coppola G; Franzoni E; Verrotti A; Garone C; Sarajlija J; Operto FF; Pascotto A Brain Dev; 2007 Jun; 29(5):281-4. PubMed ID: 17055681 [TBL] [Abstract][Full Text] [Related]
33. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine. Keränen T; Sorri A; Moilanen E; Ylitalo P Arzneimittelforschung; 2010; 60(7):421-6. PubMed ID: 20712131 [TBL] [Abstract][Full Text] [Related]
35. Oxcarbazepine in combination with Tiaprid in inpatient alcohol-withdrawal--a RCT. Croissant B; Loeber S; Diehl A; Nakovics H; Wagner F; Kiefer F; Mann K Pharmacopsychiatry; 2009 Sep; 42(5):175-81. PubMed ID: 19724979 [TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415 [TBL] [Abstract][Full Text] [Related]
37. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms. Yang X; Yan Y; Fang S; Zeng S; Ma H; Qian L; Chen X; Wei J; Gong Z; Xu Z Medicine (Baltimore); 2019 Mar; 98(12):e14908. PubMed ID: 30896644 [TBL] [Abstract][Full Text] [Related]
38. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647 [TBL] [Abstract][Full Text] [Related]
39. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Dogan EA; Usta BE; Bilgen R; Senol Y; Aktekin B Epilepsy Behav; 2008 Jul; 13(1):156-61. PubMed ID: 18331816 [TBL] [Abstract][Full Text] [Related]
40. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]